[Experimental study on the treatment of human hepatocellular carcinoma by fibroblast-mediated human IFN-alpha gene therapy in combination with adoptive chemoimmunotherapy].
In the present study, we observed the therapeutic effect of the fibroblast-mediated human IFN alpha gene therapy in combination with IL-2/AK/DOX adoptive chemoimmunotherapy on human hepatocellular carcinoma-bearing nude mice. Activated killer cells (AK) were prepared from human peripheral mononuclear cells co-stimulated in vitro with IL-2 and inactivated human hepatocellular carcinoma SMMC 7721 cells. The results demonstrated that (1) When the NIH3T3-IFN-alpha+ cells were implanted i.p. to the tumor-bearing nude mice, the growth of tumor was inhibited and the survival time of the mice was prolonged; (2) The growth of tumor was significantly inhibited when AK was injected i.v. and IL-2 was injected i.p. after the NIH3T3-IFN-alpha+ cells had been implanted; (3) The best therapeutic results could be achieved when NIH3T3-IFN-alpha+ cells were used in combination with IL-2/AK/DOX. All these results suggeste that the fibroblast-mediated human IFN-alpha gene therapy could be used to treat human hepatocellular carcinoma but better results can be obtained when used in combination with IL-2-based immunotherapy.
Wang
J
J
Department of Immunology, Second Military Medical University, Shanghai.
Cao
X
X
Kong
X
X
D016475:3T3 Cells; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D016898:Interferon-alpha / Q000235:genetics*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D014407:Tumor Cells, Cultured
D016898:Interferon-alpha